Navigation Links
ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
Date:9/16/2010

ndomized at a ratio of 1:1:1 to receive either bromfenac or placebo in both eyes twice daily and will be evaluated over the course of 42 days.  For both efficacy studies, the objective sign of conjunctival staining will be measured using the Lissamine Green test and subjective symptoms will be measured using the Ocular Surface Disease Index (OSDI). ISTA anticipates reporting results in the middle of 2011.  

The two remaining Phase 3 safety studies are the subject of additional SPAs currently under review by the FDA. To meet FDA guidance on drugs for chronic dosing, the Company expects to conduct both a six-month and a twelve-month safety study. ISTA anticipates it will initiate one or both of these safety studies later this year, subject to reaching agreement with the FDA on the SPAs.

ABOUT DRY EYE DISEASE

Dry eye occurs when there is an imbalance of tears that provides moisture and lubrication to the eye, which can result in pain, itching, redness, blurry vision, light sensitivity and/or a gritty sensation or feeling of sand in the eye.  Causes for dry eye include environmental conditions such as air conditioning, smoke and dust, aging and menopause, side-effects from antihistamines and birth control pills, Sjogren's syndrome, rheumatoid arthritis and structural problems with the eye lid's ability to close. Left untreated, dry eye can lead to abrasions on the surface of the eye and damage to the cornea. Current treatments include artificial tears and ointments, topical steroids, a topical immunomodulator that is the only approved prescription eye drop treatment and punctal occlusion (closing or plugging of tear drains).  

ABOUT BROMFENAC OPHTHALMIC SOLUTION

REMURA (bromfenac ophthalmic solution for dry eye) is a sterile, topical non-steroidal anti-inflammatory (NSAID) compound under investigation for use as an ophthalmic agent to alleviate the signs and symptoms of dry eye disease. Since 2
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. Access Pharmaceuticals Launches MuGard Product Website
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
7. ARCADIS Jane Staveley to Moderate Congressional Briefing on Pharmaceuticals in Drinking Water
8. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
9. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is ... a non-profit organization providing grief camps for kids, teens, adults, ... suffering our clients experience from the death of a loved ... organization like Stepping Stones of Hope, as they provide hope ... of Hope also includes a monthly support group and a ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... most cases of cancer is to surgically remove the ... that the surgeon may fail to extract the entire ... new technique, researchers at the University of Pennsylvania have ... entire tumor in the patient, increasing the likelihood of ... dye that accumulates in cancerous tissues much more so ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... risk of dementia according to recent research. // ,People ... risk of dementia and Alzheimer’s disease. ,DHA or docosahexaenoic ... that is required for the proper functioning of the central ... issue of the Archives or Neurology. ,According to lead ...
... An Austrian study points out that the risk of developing ... results of the study done by researchers from Medical University ... ,The study found out that marathon runners have increased chances ... .Both liver spots and moles reflect a higher risk to ...
... virus boost the cancer-killing abilities of existing cancer drugs? ... on Molecular Targets and Cancer Therapeutics, in Prague, Czech ... may lead to more effective treatment options for patients ... in which malignant (cancer) cells form in the tissues ...
... law to register all health care infrastructure in the country ... // ,"The act named as the Clinical Establishment Act ... and will register all health care institutes, infrastructure and human ... in a function entitled "Public Health Initiative: PPP model"., ...
... Hobart Hospital who are attending to babies born to ... the babies are discharged from the hospital. It is ... addictions at the hospital annually., ,The director ... Peter Dargaville, said, "We see the most severely affected ...
... that more than two thirds of the Britons fearing heart ... an ambulance. //The reluctance in calling emergency help have proved ... to be the biggest killer, often killing at least one ... ,The poll was conducted under the BHF's 'Doubt Kills' ...
Cached Medicine News:Health News:Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs 2
... Sodium Hyaluronate (1.8%) viscoelastic solution combines maximum ... Rayflo maintains a deep anterior chamber and ... is ideal for routine cataract surgery but ... requiring a viscoelastic. Combine all these properties ...
... Healon5 is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average molecular ... Healon5 contains 23 mg/mL of sodium ... units of N-acetylglucosamine and sodium glucuronate ...
... is a highly retentive, dispersive viscoelastic. ... weight, low pseudoplasticity and low surface ... and excellent tissue protection. It is ... (catalog number 8065183905) or as part ...
... planning workstation is used to plan precisely ... Planning Workstation, the surgeon can simulate the ... the patient. This enables the selection of ... material waste and procedural costs. The surgeon ...
Medicine Products: